ActHIB

Clinical Pharmacology

font size

Clinical Pharmacology

ActHIB

75%

TABLE 2¹⁷

ANTI-PRP ANTIBODY RESPONSES IN 2- MONTH- OLD INFANTS NIH TRIAL IN MINNESOTA, MISSOURI AND TEXAS
GEOMETRIC MEAN TITER (GMT) (µg/ mL)
VACCINE	N*	Pre- Immunization	Post Second Immunization	Post Third ^§ Immunization	Post Third ^§ Immunization %>1.0µg/mL
PRP-T^† (ActHIB^®)	142	0.25	1.25	6.37	97%
PRP-OMP (PedvaxHIB^® )	149	0.18	4.00	N/A	85%**
HbOC^† (HibTITER^®)	167	0.17	0.45	6.31	90%

* N= Number of Children

^§Sera were obtained after the third dose from 86 and 110 infants, in PRP-T and HbOC vaccine groups, respectively.

^†Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)

*** Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)

Brand Name: ActHIB
Generic Name: Haemophilus b Conjugate Vaccine

« Previous
Clinical Pharmacology
Next »

Next: ActHIB - Patient Information »
« Previous: ActHIB - Overdosage & Contraindications

Bookmark this page:

WebMD Resources

Overscheduled Families
Do you run your kids from one activity to another, day after day? If so, you should take a minute to watch.See more WebMD Videos »